Zanolimumab: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) HuMax-CD4 is most likely not a trade name, it only means "human monoclonal antibody against CD4"; slightly expanded; additional source |
Anypodetos (talk | contribs) Sourced trade name HuMax-CD4 |
||
| Line 26: | Line 26: | ||
| routes_of_administration = |
| routes_of_administration = |
||
}} |
}} |
||
'''Zanolimumab''' is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]]. It is being developed for the treatment of [[rheumatoid arthritis]], [[psoriasis]], cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> |
'''Zanolimumab''' (expected trade name '''HuMax-CD4'''<ref>[http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx Genmab initiates Phase II Study with HuMax-CD4]</ref>) is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]]. It is being developed for the treatment of [[rheumatoid arthritis]], [[psoriasis]], cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> |
||
== References == |
== References == |
||
Revision as of 14:00, 14 October 2009
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Molar mass | 147 kDa |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, cutaneous and peripheral T-cell lymphoma.[2][3]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |